Alzheimer’s disease (AD) is one of the major causes of death that currently cannot be reversed or slowed. Fornix, a major output tract of the hippocampus, has been shown to be a promising target for DBS therapy in AD patients. In this study, triple-transgenic Alzheimer’s mice were used to investigate the changes of white matter integrity and the cognitive functions after the DBS-fornix therapy. We found improvement of the cognition and increased white matter integrity after that DBS-fornix therapy in AD mice. It suggested that the DBS-fornix therapy may be a potential therapeutic intervention of AD.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords